Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Septimeb for severe or very severe COVID-19
IRCT20200324046847N1Phase 2Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Septimeb in coronavirus disease 2019 (COVID-19), sponsored by Tehran University of Medical Sciences. Primary endpoints: Number of admission days, Mortality rate and 1 more. Started Mar 2020; status: completed.
02
Drugs
Septimeb
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20200324046847N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200324046847N1.